rebound pharma china
core growth opm ep ahead est
sale yoy fx vs our/street estimate
core growth vs estimate guid gm adj
opm yoy yoy respect volum
price off-set dilut non-gaap ep vs our/street
est overal solid rebound softer reaffirm
posit view compani lst life scienc tool space overal
execut well key growth driver pharma shine
quarter led agil two biggest import end-market pharma
organ sale growth like share gain compet
chemic growth despit tough comp addit
rais concern china last quarter region grew off-set
continu soft environment forens flat academ government
food continu lag due reorg chines government ministri
beyond end-market larg stabl focu call china tariff impact
agil emphas seen chang custom buy behavior
step taken off-set higher duti result impact
expect ep impact net annual hit
revenu chang suppli chain price
adjust est reiter buy setup look good
agil rais core revenu growth guid vs prior rais adj
ep new midpoint prior guid core growth
given easier sequenti comp vs like
conserv overal see major tool end-market strong manag
tariff headwind key agil product busi continu perform well
easi comp make favor setup could see upsid surpris
guid wave recent deal begin contribut organ growth rais
revenu ep reiter
buy rate po remain unchang still base ev/ebitda
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart santa clara california agil
technolog lead supplier analyt
instrument consum product
use mainli research qualiti assur
applic custom life scienc
chemic analysi industri compani
known leader life scienc
industri long histori innov
well posit benefit
secular posit growth trend life
scienc chemic analysi food
environment test acquisit also
provid new opportun growth
under-penetrated market agil reduc
cyclic exposur restructur
spin electron test measur
busi keysight help unlock sharehold
valu increas strateg flexibl
po base ev/ebitda multipl modest premium
median valuat agil life scienc peer group
believ justifi given agil margin expans potenti upsid new gc
product cycl macro improv solid organ revenu growth outlook strateg
option opportun capit deploy execut
risk po econom risk fx risk slower expect uptak new
product expans new market competit risk reduct spend
integr risk takeout specul overhang
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
